Cempra Adds $50.8M to Push Pivotal Solithromycin Program
On Thursday, Cempra Inc. disclosed a successful end-of-Phase II meeting with the FDA, citing only the need for additional funding to proceed with the planned Phase III trial testing I.V.-to-oral administration of macrolide antibiotic solithromycin in CABP.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST